Monogenic diabetes – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:55 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Monogenic diabetes – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Increasing the dose of glimepiride for patients with HNF1A-MODY or HNF4A-MODY diabetes https://clinicaltrials.eu/trial/increasing-the-dose-of-glimepiride-for-patients-with-hnf1a-mody-or-hnf4a-mody-diabetes/ Wed, 29 Apr 2026 15:09:17 +0000 https://clinicaltrials.eu/trial/increasing-the-dose-of-glimepiride-for-patients-with-hnf1a-mody-or-hnf4a-mody-diabetes/ This study focuses on people living with Maturity-onset diabetes of the young type 3, also known as HNF1A-MODY, and Maturity-onset diabetes of the young type 1, known as HNF4A-MODY. These are rare forms of diabetes caused by specific genetic changes rather than the more common types. The research aims to evaluate how increasing the dose of a medication called glimepiride affects blood sugar levels in these individuals.

The medication used, glimepiride, belongs to a group of drugs called sulfonylureas. During the study, participants will undergo a process where their medication dose is gradually increased to find an effective amount. Blood sugar levels will be tracked using continuous glucose monitoring, which is a method that involves a small device to measure sugar levels in the body continuously over time. The study will look at how well the sugar levels stay within a healthy target range and how the medication affects overall sugar stability.

]]> Study on the Effects of Empagliflozin on Blood Sugar Levels in Patients with HNF1A-MODY Diabetes https://clinicaltrials.eu/trial/study-on-the-effects-of-empagliflozin-on-blood-sugar-levels-in-patients-with-hnf1a-mody-diabetes/ Wed, 29 Apr 2026 14:24:08 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-empagliflozin-on-blood-sugar-levels-in-patients-with-hnf1a-mody-diabetes/ This clinical trial is focused on studying the effects of a medication called empagliflozin on a specific type of diabetes known as Maturity-onset diabetes of the young type 3 (HNF1A-MODY). This form of diabetes is caused by a genetic change in the HNF1A gene, which affects how the body controls blood sugar levels. The medication being tested, Jardiance 25 mg film-coated tablets, contains the active ingredient empagliflozin, which is taken orally as a tablet. The study also involves a comparison with a placebo tablet, which looks like the medication but does not contain any active ingredients.

The purpose of the study is to investigate how well empagliflozin can lower blood sugar levels in patients with HNF1A-MODY. Participants in the study will receive both the medication and the placebo at different times, without knowing which one they are taking, to compare the effects. This type of study is called a “double-blind, crossover trial,” meaning neither the participants nor the researchers know who is receiving the medication or the placebo at any given time, and participants will switch between the two during the study.

The study will last for several months, during which participants will have their blood sugar levels monitored using a method called continuous glucose monitoring (CGM). This involves wearing a small device that tracks blood sugar levels throughout the day and night. The study aims to see if there is a significant difference in blood sugar control when taking empagliflozin compared to the placebo. Other factors, such as body weight and the occurrence of low blood sugar events, will also be observed to understand the overall impact of the medication.

]]>